Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules

• US 5,908,623 A
• Filed: 05/25/1995
• Issued: 06/01/1999
• Est. Priority Date: 08/12/1993
• Status: Expired due to Term

• Current Assignee: Neurotech USA, Inc. (Woodbrook Group Holdings, Inc.)
• Original Assignee: Cytotherapeutics, Inc.
• Inventors: Emerich, Dwaine F., Hammang, Joseph P., Gentile, Frank T., Baetge, Edward E., Lindner, Mark D., Winn, Shelley R.
• Primary Examiner(s): Stanton, Brian R.
• Assistant Examiner(s): REYNOLDS, DEBORAH J
• Application Number:
  US08/450,862
• Time in Patent Office: 1,468 Days
• Field of Search: 424/93.21, 424/408, 424/422, 424/424, 424/93.1, 424/93.2, 435/284.1, 435/285.1, 514/44
• US Class Current: 424/93.21
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0085 Brain, e.g. brain implants; Spinal cord
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: C07K 14/48 Nerve growth factor [NGF]
• CPC Class Codes: C07K 14/70 Enkephalins
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal. In addition, this invention provides a general means for maintaining, for extended periods of time, the in vivo expression of transgenes.

Claims

1. A method for delivering a neurotrophic factor to the striatum of a mammalian host, the method comprising implanting at least one biocompatible capsule into the striatum of the host, each capsule comprising

(a) a core comprising living mammalian cells secreting said neurotrophic factor, the cells having been transfected with a recombinant DNA molecule comprising a DNA sequence encoding said neutrotrophic factor operably linked to a promoter and wherein said cells stably express said neurotrophic factor;

and

(b) a biocompatible jacket surrounding the core, the jacket comprising a permselective membrane permitting passage of the neurotrophic factor thereacross into the host.

2. The method of claim 1 wherein the cells are xenogeneic to the host.

3. The method according to claim 1 wherein the neurotrophic factor is nerve growth factor (NGF).

4. The method according to claim 1 wherein the cells are BHK cells.

5. The method according to claim 1 wherein the neurotrophic factor is selected from the group consisting of nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), glial derived neurotrophic factor (GDNF), brain derived neurotrophic factor (BDNF), neurotrophic factor-3 (NT-3), neurotrophic factor -4/5 (NT-4/5), epidermal growth factor (EGF), CDF/LIF, insulin-like growth factor (IGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), platelet derived growth factor (PDGF), transforming growth factor (TGF), neurotensin, and Substance P.

6. The method of claim 1 wherein the jacket material is selected from the group consisting of polyacrylates, polyvinylidenes, polyvinylchloride copolymers, polyurethanes, polystyrenes, polyamides, cellulose acetates, cellulose nitrates, polysulfones, polyphosphazenes, polyacrilonitriles, poly (acrilonitrile/convinyl chloride), and derivatives, copolymers and mixtures thereof.

7. The method of claim 1 wherein the jacket is shaped to form a hollow fiber.

8. The method of claim 1 wherein the jacket is shaped to form a flat sheet.

9. The method of claim 1 wherein between one and six capsules are implanted in the straiatum of the host.